A Study for the Collection of Clinical Data for Stroke Patients and Healthy Subjects

Sponsor
Bundang CHA Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05908994
Collaborator
(none)
100
1
38.8
2.6

Study Details

Study Description

Brief Summary

This study aimes to medical data, musculoskeletal data and functional data over time of stroke patients and healthy subjects to compared the clinical differences between stroke and healthy subjects.

Condition or Disease Intervention/Treatment Phase
  • Other: Examination

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Study for the Collection of Clinical Data for Stroke Patients and Healthy Subjects
Actual Study Start Date :
Oct 6, 2021
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Outcome Measures

Primary Outcome Measures

  1. Changes in motion analysis [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    Motion analysis is a process of measuring and evaluating gait function in kinetic and kinematic parameters

Secondary Outcome Measures

  1. Changes in X-ray radiography [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    X-ray radiography is a process of measuring and detecting the structural changes of bones including thorax, whole spine, lower extremity

  2. Changes in computed tomogrphy (CT) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    CT scan is a process of measuring and detecting the structural changes of spine

  3. Changes in magnetic resonanace imaging (MRI) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    MRI scan is a process of measuring changes of diffusion tensor tractography

  4. Changes in manual muscle test (MMT) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    MMT is a process of the evaluating the function and strength of individual muscles and muscle groups based on the effective performance of a movement in relation to the forces of gravity and manual resistance in score

  5. Changes in motricity index (MI) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    MI is a process of the evaluating the function and strength of upper, lower extremities and trunk in score

  6. Changes in range of motion (ROM) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    ROM testing is a measurement of movement around a specific joint of body part in angle

  7. Changes in berg balance scale (BBS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    BBS is a measurement of balancing function. A five-point ordinal scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. Total score = 56

  8. Changes in motor assessment scale (MAS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    MAS is a measurement of performance-based scale for assessing everyday motor function. The MAS is comprised of 8 items corresponding to 8 areas of motor function. All items are assessed using a 7-point scale from 0-6.

  9. Changes in trunk impairment scale (TIS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    MAS is a measurement of static and dynamic sitting balance and trunck coordination in a sitting position. For each item, a 2-, 3- or 4- point ordinal scale is used. The total score for TIS ranges between 0 for a minimal performance to 23 for a perfect performance.

  10. Changes in functional ambulatory category (FAC) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    FAC is a measurement of a functional walking test that evaluates ambulation ability. This 6-point scale assesses ambulation status by determining how much human support the patient requires when walking, regardless of whether or not they use personal assistive device.

  11. Changes in Gait rite [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    Gait rite is a measurement of a temporal and spatial parameters during gait

  12. Changes in time up and go test (TUG) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    TUG is a measurement of a person's mobility and requires both static and dynamic balance. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. 11-20 seconds are within normal limits for frail elderly and disables patients, and greater than 20 seconds means the person needs assistance outside and indicates further examintaiton and intervention. A score of 30 seconds or more suggests that the person may be prone to falls.

  13. Changes in Fugl-meyer assessement (FMA) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    FMA is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sesation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research determine disease severity, describe motor recovery, and to plan and assess treatment.

  14. Changes in action research arm test (ARAT) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    ARAT is a 19 item observational measurement to assess upper extremity performance (coordination, dexterity and functioning). Items comprising ARAT are categorized into four subscales (grasp, grip, pinch and gross movement). Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performend normally)

  15. Changes in fuctional independence meausure (FIM) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    FIM is a measurment to evaluate the funciontional status. FIS is an 18-item including functional capability in six areas of self-care, continence, mobility, transfers, communication and cognition. Each of the 18 items are graded on a scale of 1-7, based on the level of independence in that item

  16. Changes in modified barthel-index (MBI) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    MBI is a measurement of degree of independence of a patient from any assistance. It covers 10 domains of daily activities: bowel and bladder control, grooming, toilet use, feeding, trasnfers, walking, dressing, climbing stairs and bating

  17. Changes in national institute of health care stroke scale (NIHSS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    NIHSS is a measurement for assessing the severity of stroke patients. The scale is made up of 11 different elements that evaluate specific ability. The score for each ability is a number between 0 and 4, 0 being normal functioning and 4 being completely impaired. 42 is the highest score possible, the higher the score, the more impaired a stroke patient is.

  18. Changes in stroke specific quality of life (SS-QoL) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    SS-QoL is an instrument designed to measure th quality of life (QOL) of stroke population and is intended to identify common areas that affect health-related QoL. The assessment is composed of 49 items within 12 domains that include such items as energy, family roles, mobility, and self-care. The SS-QoL has a score range of 49 to 245 with higher scores indicating better HR-QoL.

  19. Changes in Korean version of Montreal cognitive assessment (K-MoCA) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    K-MoCA is a measurement to evaluate the memory loss or other symptoms of cognitive decline. It contains 30 questions and taskes around to 12 minutes to complete. Scores range from 0 to 30. A score of 26 and higher is considered normal.

  20. Changes in Korean version of mini-mental state examination (K-MMSE) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    K-MMSE is a measurement of cognitive level. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe(≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment. The raw score may also need to be corrected for educational attainement and age.

  21. Changes in clinical dementia rating (CDR) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    CDR is a rating scale for staging patients diagnosed with dementia. The CDR evaluates cognitive, behavioral and functional aspects of Alzheimer disease and other dementias. It is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem sloving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), MCI (CDR = 1), moderate cognitive impairment (CDR = 2) and severe cognitive impairment (CDR = 3)

  22. Changes in global deterioration scale (GDS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    GDS is a clinical rating instrument created to assess stages of primary degenerative dementia, namley, Alzhemier's disease (AD). It is classified seven stages: stage 1 (no cognitive decline), stage 2 (very mild cognitive decline), stage 3 (mild cognitive decline), stage 4 (moderated cognitive decline), stage 5 (moderately severe cognitive decline), stage 6 (severe cognitive decline), stage 7 (very severe cognitive decline)

  23. Changes in geriatric depression scale (GDS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    GDS is a 30-item self-report assessment used to identify depression in the elderly. One point is assigned to each answer and the cumulative score is rated on a scroing grid. The grid sets a range of 0-9 as "normal", "10-19" as "mildly depressed", and 20-30 as "severely depressed".

  24. Changes in Oxford cognitive screen (OCS) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    OCS is an assessment of major cognitive domains of memory, language, number, praxis, executive functions and attention.

  25. Changes in Korean version of Wechsler adult intelligence scale 4th edition (K-WAIS-IV) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    K-WAIS-IV is a measurment for intelligence and cognitive ability in adults and older adolscents. There are four index scores representing major components of intelligence including verbal comprehension index, perceptual reasoning index, working memory index, processing speed index.

  26. Changes in Rey-kim test [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    Rey-kim test is a measurement for assessing memory quotient including auditory verbal learning test and complex figure test

  27. Changes in digit span test [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    Digit span test is a measurment to assess the storage capacity of a person's working memory. A testperson is visually or auditorily to a sequence of digits on after another. Right afterwards, the test subject has to recall the correct digits in the same order.

  28. Changes in stroop test [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    Stroop test is a meausrment to assess the ability to inhibit cognitie interference. The stroop test consists of colors that are writen in words but in the wrong color ink, The test-taker has to be able to state the color that the word is written in and be able to ignore whatever the actual word is.

  29. Changes in electroencephalogrphy (EEG) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    EEG is a measurement of electrical activity in the brain using small electrodes attached to the scalp for diagnosting brain disorders.

  30. Changes in evoked potentials (EP) [Change from baseline to 6 months, 12 months, 18 months and 24 months]

    Measurement evoked potentials including sensory and motor evoked potentials. An evoked potential is the electrical response fo the brain to a sensory or motor stimulus.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
  1. For stroke patients 1) Inclusion Criteria:
  • Adults over 20 years of age

  • More than 1 month after onset of stroke

  • After hearing a detailed explanation of this study and fully understanding it, the subject or legal representative voluntarily decides to participate and agrees in writing to observe the precautions 2) Exclusion criteria:

  • Patients who correspond to one or more of the following cannot participate in the study.

  • Patients with systemic infectious symptoms at the time of participation in the study

  • In the case of a person with impaired ability to consent (less than 10 points on the MMSE), a person who is not accompanied by a guardian

  • Those with severe medical conditions such as unstable conditions in the cardiovascular system, digestive system, respiratory system, endocrine system, etc., and those with poor general health

  • Other cases where the researcher judges that participation in this study is not suitable(Patients who are participating in other clinical trials or studies, or who have participated in other clinical trials or studies within the past 30 days can also participate in this study.)

  1. For healthy voluteers 1) Inclusion Criteria:
  • Over 20 years of age

  • A person who is performing an independent daily life

  • A person who voluntarily decides to participate and agrees in writing to abide by the precautions after hearing a detailed explanation of this study and fully understanding it

  1. Exclusion criteria:
  • Patients who correspond to one or more of the following cannot participate in the study.

  • MMSE score less than 20 points (from 19 points onwards excluded from study)

  • Those who remain disabled due to brain disease (stroke, brain tumor, cerebral palsy, dementia, Parkinson's disease, etc.)

  • Those with severe medical conditions such as unstable conditions in the cardiovascular system, digestive system, respiratory system, endocrine system, etc., and those with poor general health

  • Other cases where the researcher judges that participation in this study is not suitable (Patients who are participating in other clinical trials or studies, or who have participated in other clinical trials or studies within the past 30 days can also participate in this study.)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Rehabilitation Medicine, CHA Bundang Medical Center Seongnam Korea, Republic of 13496

Sponsors and Collaborators

  • Bundang CHA Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
MinYoung Kim, MD, PhD, Principle investigator, Bundang CHA Hospital
ClinicalTrials.gov Identifier:
NCT05908994
Other Study ID Numbers:
  • 2021-05-026
First Posted:
Jun 18, 2023
Last Update Posted:
Jun 18, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2023